Creo Medical Group (FRA:1RC) Tariff Resilience Score: 0/10 (As of Jul. 09, 2026)


FRA:1RC Creo Medical Group PLC FRA:1RC
52 GF Score
Price €0.16
GF Value €0.19
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Tariff Resilience Score?

Creo Medical Group has the Tariff Resilience Score of 0, which implies that the company might have .

Creo Medical Group has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Creo Medical Group might have .

Creo Medical Group  (FRA:1RC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Creo Medical Group Tariff Resilience Score Related Terms

FRA:1RC
52GF Score
Creo Medical Group PLC FRA:1RC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Creo Medical Group (FRA:1RC) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of €0.16 is trading 16.8% below its estimated GF Value™ of €0.19.

Key valuation signals for FRA:1RC:

  • Tariff Resilience Score: 0
  • GF Value™: €0.19 vs. price of €0.16 (16.8% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the FRA:1RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score

Get the complete analysis for FRA:1RC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.16
Price
€0.19
GF Value